Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial by Nan Niu, Jinqi Xue, Guanglei Chen, Fang Qiu, Qianshi Xu, Xinyu Zheng, Chao Liu, Yafei Zhao, Xi Gu, Yi Zhao, Hong Xu, Hao Zhang, Guijin He, Ke Li, Pengfei Li, Xiaoying Chen, Yong Li, Shuo Wang, Demiao Zhu, Tong Liu, Fei Xing, Yongqing Xu, Ye Han, Meiyue Tang, Mingxin Liu, Gege Jiao, Xiaofan Jiang, Tony Yuen, Zheng Pang, Caigang Liu

Get full text